• Pitt
  • Health Sciences
  • UPMC
Regenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan Institute
  • Home
  • Our People
    • Faculty/Staff Bios
    • Core Faculty Publications
    • Administrative Resources
  • Our Technologies
  • About Us
    • Welcome
    • Video
    • Mission Statement
    • What Is Regenerative Medicine?
    • Executive Committee
    • Contact Us
    • Clinical Site
  • Our Research
    • Focus Areas
      • Tissue Engineering and Biomaterials
      • Cellular Therapies
      • Medical Devices and Artificial Organs
      • Clinical Translation
    • Matrix
    • Centers
    • Laboratories
    • Clinical Trials
    • Initiatives
  • Media
    • Current News
    • News Archive
    • Video
    • Podcasts
    • Newsletter
    • Grant of the Month
    • Publication of the Month
    • Media Contact
    • Video Links
  • Professional Development
    • Seminar Series
    • Special Events
    • Student Interest Groups
    • CATER
    • Post-Doctoral Opportunities
    • Career Opportunities
    • Wiegand Summer Internship
    • Admissions
    • Summer School
    • 2021 Scientific Retreat

Grant of the Month |October 2020

    Home Grant of the Month Grant of the Month |October 2020

    Grant of the Month |October 2020

    By The McGowan Institute For Regenerative Medicine | Grant of the Month, Grant of the Month 2020 | Comments are Closed | 26 October, 2020 | 0

    PIs: D. Lansing Taylor, Jaideep Behari, and Alejandro Soto-Guttierrez

    Title: A Vascularized Patient-Derived iPSC Liver Acinus Microphysiological System as an Innovative Precision Medicine Platform for Optimizing Clinical Trial Design for Nonalcoholic Fatty Liver Disease

    Description: A vascularized patient-derived iPSC liver acinus microphysiology system (vLAMPS) is an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease (NAFLD). Non-alcoholic fatty liver disease (NAFLD) is a major health crisis with no approved therapeutics and many failures in the clinic. The prevalence of NAFLD is estimated to increase from 25% of the US population in 2015 (~83 million) to over 100 million by 2030, accompanied by an increase in nonalcoholic steatohepatitis (NASH), the progressive form of the disease, that can lead to cirrhosis with liver failure and hepatocellular carcinoma (HCC). Despite its public health importance, there is currently no FDA-approved therapy for any stage of NAFLD. NAFLD/NASH is a complex heterogeneous disorder involving multiple molecular pathways. Development of efficacious pharmacotherapy has been hampered by the limited utility of preclinical drug testing models. Simple cell culture and animal models do not recapitulate the spectrum of NASH phenotypes in humans. Highlighting these species differences, knock-in murine models with the high-risk NASH-associated genetic polymorphism, PNPLA3 I148M, develop hepatic steatosis but do not recapitulate the progressive disease seen in humans. Additionally, heterogeneity in risk of progression of NASH, individual genetic variations modulating risk of fibrosis progression, and presence of NAFLD-associated metabolic comorbidities such as Type 2 diabetes mellitus (T2DM), adds additional complexity. We will implement the vLAMPS to initially characterize both a “normal” and a NAFLD/NASH vLAMPS generated from primary human liver cells (hepatocytes, liver sinusoidal endothelial cells, stellate and Kupffer cells) and then reproduce the results with induced pluripotent stem cells (iPSCs). We will ultimately generate patient-specific iPSCs of the four cell types from patients in our NAFLD clinic to create patient-specific vLAMPS. We will test two cohorts: 1) patients with the PNPLA3 I 148M variant and 2) patients with the wild-type PNPLA3 to identify the patients who respond to two NAFLD drugs that have or are now going through clinical trials and two control drugs. Importantly, this paradigm circumvents the conundrum of high-risk patients being enrolled in large prolonged studies with a high likelihood of failure being simultaneously disqualified from other potentially beneficial studies/treatments. This approach will prove transformational for clinical trial design by enriching for subjects most likely to benefit from a therapy, and in the future, after more than one currently investigational drugs are approved, for precision medicine to identify the most efficacious therapy for high-risk subgroups.

    Source: National Center for Advancing Translational Sciences

    Term: July 15, 2020 – June 30, 2022

    Amount: $748,638 FY

    Print Friendly, PDF & Email
    No tags.

    The McGowan Institute For Regenerative Medicine

    More posts by The McGowan Institute For Regenerative Medicine

    • site map
    • links
    • contact
    • subscribe to our newsletter
    © Copyright 2021 McGowan Institute for Regenerative Medicine
    A program of the University of Pittsburgh and the University of Pittsburgh Medical Center
    • Home
    • Our People
      • Faculty/Staff Bios
      • Core Faculty Publications
      • Administrative Resources
    • Our Technologies
    • About Us
      • Welcome
      • Video
      • Mission Statement
      • What Is Regenerative Medicine?
      • Executive Committee
      • Contact Us
      • Clinical Site
    • Our Research
      • Focus Areas
        • Tissue Engineering and Biomaterials
        • Cellular Therapies
        • Medical Devices and Artificial Organs
        • Clinical Translation
      • Matrix
      • Centers
      • Laboratories
      • Clinical Trials
      • Initiatives
    • Media
      • Current News
      • News Archive
      • Video
      • Podcasts
      • Newsletter
      • Grant of the Month
      • Publication of the Month
      • Media Contact
      • Video Links
    • Professional Development
      • Seminar Series
      • Special Events
      • Student Interest Groups
      • CATER
      • Post-Doctoral Opportunities
      • Career Opportunities
      • Wiegand Summer Internship
      • Admissions
      • Summer School
      • 2021 Scientific Retreat
    Regenerative Medicine at the McGowan Institute